scholarly journals Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer

The Prostate ◽  
2020 ◽  
Vol 80 (5) ◽  
pp. 407-411
Author(s):  
Mark C. Markowski ◽  
Eugene Shenderov ◽  
Mario A. Eisenberger ◽  
Sushant Kachhap ◽  
Drew M. Pardoll ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Castration Resistant Prostate Cancer ◽  
Androgen Therapy ◽  
Castration Resistant ◽  
Extreme Responses

scholarly journals Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer

2020 ◽  
Vol 12 ◽  
pp. 175883592093608
Author(s):  
Harry J. Han ◽  
Yun Rose Li ◽  
Mack Roach ◽  
Rahul Aggarwal
Keyword(s):  
Prostate Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Response To Treatment ◽  
Small Subset ◽  
Castration Resistant Prostate Cancer ◽  
Durable Response ◽  
Castration Resistant ◽  
Previously Treated

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have demonstrated anti-tumor activity in several advanced solid malignancies. In previously treated metastatic castration resistant prostate cancer (mCRPC), a small subset of patients have a therapeutic response to checkpoint inhibition. Those who do respond to anti-PD-1/PD-L1 therapy have a marked, durable response to treatment, suggesting some derive long-term benefit from immune checkpoint blockade. In other cancers, one strategy to increase the efficacy of immune checkpoint blockade is to combine it with a pro-immune stimulatory agent, such as radiation. Here we present a case of a patient with heavily treated mCRPC who had a significant tumor response to concurrent pembrolizumab and radiation therapy to the primary prostatic mass. We review the growing evidence supporting the use of this combination therapy in other cancers and its potential benefit and safety in mCRPC. Our report highlights a potential therapeutic approach that should be further investigated in previously treated mCRPC.

scholarly journals Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer

Nature Cancer ◽  
2021 ◽  
Author(s):  
Yuanyuan Qiao ◽  
Jae Eun Choi ◽  
Jean C. Tien ◽  
Stephanie A. Simko ◽  
Thekkelnaycke Rajendiran ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Autophagy Inhibition

Beyond immune checkpoint blockade: New approaches to targeting host-tumor interactions in prostate cancer: Report from the 2014 Coffey-Holden prostate cancer Academy meeting

The Prostate ◽  
2014 ◽  
Vol 75 (4) ◽  
pp. 337-347 ◽  
Author(s):  
Andrea K. Miyahira ◽  
Haydn T. Kissick ◽  
Jennifer L. Bishop ◽  
David Y. Takeda ◽  
Christopher E. Barbieri ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
New Approaches
Sign in / Sign up

Export Citation Format

Share Document